News Brief: WEX Pharmaceuticals Inc. Enrolls In Korea As Part Of The Multinational Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain March 21, 2023 Read more
News Brief: WEX Pharmaceuticals Inc. Enrolls The First Patient In The Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain January 3, 2023 Read more
News Brief: Wex Pharmaceuticals Inc. Announces Authorization For The Conduct Of A Chemotherapy-induced Neuropathic Pain Clinical Trial In China, Singapore, Taiwan, Korea, Usa, And Canada November 30, 2022 Read more
News Brief: Wex Pharmaceuticals Inc. Announces A Scientific Poster Presentation At The IASP World Congress On Pain On Its Lead Compound, Halneuron® September 22, 2022 Read more
News Brief: Wex Pharmaceuticals Inc. Announces Abstract And Poster Presentation At The IASP World Congress On Pain On The Lead Compound, TTX (Halneuron )® August 31, 2022 Read more
